Quick Answer
Aldeyra Therapeutics, Inc. reported Cash and Equivalents of $47.36 million for fiscal year 2018.
Aldeyra Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2018 | $47.36M | +136.5% |
| 2017 | $20.02M | +66.7% |
| 2016 | $12.02M | -18.0% |
| 2015 | $14.65M | +71.8% |
| 2014 | $8.53M | +161.4% |
| 2013 | $3.26M | +166.6% |
| 2012 | $1.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2019 | $39.40M | +60.1% | -11.1% |
| March 31, 2019 | $44.30M | +111.3% | -6.5% |
| December 31, 2018 | $47.36M | +136.5% | +163.0% |
| September 30, 2018 | $18.01M | -45.6% | -26.8% |
| June 30, 2018 | $24.61M | +68.4% | +17.4% |
| March 31, 2018 | $20.96M | +8.6% | +4.7% |
| December 31, 2017 | $20.02M | +66.7% | -39.5% |
| September 30, 2017 | $33.10M | +127.2% | +126.6% |
- Aldeyra Therapeutics, Inc. showed an increase of +136.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2018 period, Aldeyra Therapeutics, Inc.’s cash and equivalents has grown by 3770.2% (from $1.22 million to $47.36 million).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2018 report (Form 10-K), filed with the SEC on March 8, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: